Navigation Links
MedAvante Names Leading Expert to Head Neurocognition Therapeutic Area
Date:1/10/2011

HAMILTON, N.J., Jan. 10, 2011 /PRNewswire/ -- MedAvante, Inc., the leader in centralized expert evaluation of treatments for central nervous system (CNS) disorders, announced the appointment of Christopher Randolph, PhD, ABPP-CN, to the new position of Vice President, Neurocognition.  Dr. Randolph will lead a growing team of clinical and training experts and experienced, calibrated clinicians focusing on Alzheimer's disease (AD), mild cognitive impairment (MCI) and other neurocognitive disorders.

"MedAvante has made a serious commitment to helping drug developers in this vital therapeutic category reduce their risk of failure due to inconclusive trial results," said Paul M. Gilbert, Chief Executive Officer of MedAvante.  "Chris Randolph is a highly accomplished, widely recognized expert in Alzheimer's disease clinical trials, and he brings with him a wealth of domain expertise as well as a highly successful study track record."

"Having Chris Randolph join our senior scientific leadership team ideally complements MedAvante's science-driven methodologies that are bringing about a paradigm shift in the way CNS clinical trials are conducted," said Gilbert.  

Dr. Randolph is the author of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), a brief neurocognitive battery used widely around the world.  He has consulted on test development for over 20 years, including the revisions of the Wechsler intelligence and memory scales.  His extensive experience in CNS clinical trials includes work as an investigator and consultant, as well as creating and supervising rater training programs for a large number of Phase 2 and Phase 3 multinational studies in AD, schizophrenia, stroke, hepatic encephalopathy, and traumatic brain injury.

"The landscape of CNS clinical trials has changed substantially over the last 10-15 years, particularly in Alzheimer's disease," said Dr. Randolph.  "Today's emphasis on early diagnosis, early intervention, and the identification of disease-modifying therapies requires re-thinking traditional approaches to designing and implementing clinical trial methodologies, from the choice of endpoints to screening procedures to reducing noise in clinical assessments."

"MedAvante has a proven track record of applying a scientifically rigorous and technologically advanced approach to solving these problems in psychiatry trials," said Dr. Randolph.  "I am extremely excited by the opportunity to bring these solutions to bear upon clinical trials in AD and other neurological illnesses."

Dr. Randolph is the author of numerous peer-reviewed articles, board-certified in clinical neuropsychology and continues to serve as Clinical Professor of Neurology and Director of the Neuropsychology service at Loyola University Medical Center in Maywood, Illinois.

About MedAvante, Inc.

MedAvante is the premier global provider of centralized expert psychiatric rating and monitoring services to the pharmaceutical, biotechnology and medical device industries. Its flagship service, MedAvante Centralized Ratings, provides real-time assessments, either by telephone or videoconference, of subjects in global drug trials. Centralizing the assessors and blinding them to study protocols results in a level of standardization, calibration and objectivity that is not achievable with a decentralized group of study raters participating from unconnected investigative sites. In addition to Centralized Ratings, the company provides Continuous Quality Control (CQC), a monitoring service in which expert calibrated trainers review site-based study interviews via audio and video.  MedAvante solutions help sponsors achieve increased drug effect and reduced trial failure rates, enabling them to bring better drugs to market faster. MedAvante operates facilities in Hamilton, NJ, Madison, WI, and Moscow, Russia.  For more information, please visit www.medavante.com.


'/>"/>
SOURCE MedAvante, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study
2. Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study
3. MedAvante Launches Service to Boost Reliability of Assessments to Reduce Risk of Failed Alzheimers Disease Trials
4. MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
5. ICON and MedAvante Sign Alliance Agreement
6. Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
7. West Names New President of Pharmaceutical Packaging Systems
8. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
9. NxStage Names Joseph Turk President, North America
10. Philips Names Recipients of Its 2010 Impact Awards
11. Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... 2017   Provista , a proven leader in the ... today announced Jim Cunniff as the company,s new ... business experience to Provista, including most recently serving as the ... California . He assumed his new role with Provista ... fit for Provista," says Jody Hatcher , president, Sourcing ...
(Date:5/4/2017)... MEMPHIS, Tenn. , May 4, 2017 /PRNewswire/ ... of Infection Control, Ultraviolet-C light as ... demonstrated Tru-D SmartUVC,s ability to reduce bioburden on ... influenced bioburden reduction on high-touch, complex medical equipment ... in surgical infections. "This study further ...
(Date:5/4/2017)... , May 4, 2017  A new ... thermoplastics and other highly-engineered materials, is being launched ... tubing has been developed in recent years to ... therapies and surgical applications. More expensive materials such ... produce microextrusion tubing due to their ability to ...
Breaking Medicine Technology:
(Date:5/26/2017)... CA (PRWEB) , ... May 26, 2017 , ... Dr. ... is proud to announce a new, informational blog post on insurance options. If a ... checking insurance plans may help save time and money. Visiting an in-network provider for ...
(Date:5/26/2017)... ... 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of Bob Massey ... the creation of published authors, Bob and Margaret Massey. Bob Massey is small in ... quick and leather tough." His love for others is apparent in all of his ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “Just What Happened in the Garden of ... in the Garden of Eden” is the creation of published author, Penelope Colt, mother, trader, ... her family moved to NYC when she was three. At six, they moved to ...
(Date:5/26/2017)... ... , ... Water damage to the flooring of several classrooms at The Fort ... with a number of critical issues to address before students could return to classes. ... little or no disruption to class schedules. Second, the project had to comply with ...
(Date:5/24/2017)... Linda, Ca (PRWEB) , ... May 24, 2017 ... ... between effects and background. Understanind and choosing the most appropriate instruments for research ... prove critical in research finding. This webinar will focus on innovations in stereo ...
Breaking Medicine News(10 mins):